ETC

Recommend
Index
  • Telmidiqual<sup>®</sup>

    Telmidiqual®

    Ingredient

    Telmisartan/ Amlodipine

    Content

    40/5mg 40/10mg 80/5mg

    Indication

    Treatment of essential hypertension.

    Telmidiqual is indicated in adult patients whose blood pressure is not adequately controlled on Telmisartan or Amlodipine monotherapy

  • Tenelia M SR Tab. 10/500mg

    Tenelia M SR Tab. 10/500mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 500mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

  • Tenelia M SR Tab. 10/750mg

    Tenelia M SR Tab. 10/750mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 750mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

  • Tenelia M SR Tab. 20/1000mg

    Tenelia M SR Tab. 20/1000mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

    Content

    Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin), Metformin Hydrochloride 1000mg

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

  • Tenelia Tab. 20mg

    Tenelia Tab. 20mg

    Ingredient

    Teneligliptin Hydrobromide Hydrate

    Content

    Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin)

    Indication

    This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
    – Monotherapy
    – Combination therapy

  • Toviaz SR Tab.

    Toviaz SR Tab.

    Ingredient

    Fesoterodine fumarate

    Content

    Toviaz SR Tab. 4mg: Fesoterodine fumarate 4mg
    Toviaz SR Tab. 8mg: Fesoterodine fumarate 8mg

    Indication

    Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

  • Trental SR Tab. 400

    Trental SR Tab. 400

    Ingredient

    Pentoxifylline

    Content

    400mg

    Indication

    1) Improvement of cerebral circulation disorder (ischemia or post stroke symptoms and symptoms of cerebral arteriosclerosis like dizziness, headache, amnesia, and so on)
    2) Improvement of eye circulation disorder
    3) Improvement of peripheral arterial circulation disorder (Intermittent claudication, pain at rest, diabetic angiopathy, kraurosis, and vascular neuropathy)

  • Triapin Tab.

    Triapin Tab.

    Ingredient

    Felodipine/Ramipril

    Content

    2.5mg/2.5mg, 5mg/5mg

    Indication

    Treatment of essential hypertension.

  • Tritace Protect Tab.

    Tritace Protect Tab.

    Ingredient

    Hydroxypropylmethylcellulose-coated Ramipril Granule

    Content

    11.765mg (10mg as Ramipril)

    Indication

    1) Treatment of hypertension
    2) Treatment of heart failure post myocardial infarction
    3) Reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in patients over 55 years of age with clinical evidence of cardiovascular disease (myocardial infarction, unstable angina, past history of polyvascular coronary bypass graft or polyvascular percutaneous coronary angioplasty), stroke or peripheral vascular disease. Also reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in diabetic patients over 55 years of age who have one or more of the following clinical symptoms: Hypertension (systolic blood pressure exceeds 160mmHg or diastolic blood pressure exceeds 90 mmHg), high total cholesterol level (above 5.2 mmol/L), low high-density lipoprotein level (less than 0.9 mmol/L), smoker, history of microalbuminuria or past vascular disease
    4) Treatment of the following clinical symptoms in diabetic patients: Early nephropathy with microalbuminuria (30­300mg/24h), overt glomerular nephropathy, proteinuria (>500mg/24h)
    – Treatment of non-diabetic overt glomerular nephropathy (when creatinine clearance is 20-70 mL/min) or proteinuria (≥3g/24h)

  • Tritace Tab.

    Tritace Tab.

    Ingredient

    Ramipril

    Content

    2.5mg, 5mg

    Indication

    1) Treatment of hypertension.
    2) Treatment of heart failure post myocardial infarction
    3) Reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in patients over 55 years of age with clinical evidence of cardiovascular disease (myocardial infarction, unstable angina, past history of polyvascular coronary bypass graft or polyvascular percutaneous coronary angioplasty), stroke or peripheral vascular disease. Also reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in diabetic patients over 55 years of age who have one or more of the following clinical symptoms: Hypertension (systolic blood pressure exceeds 160mmHg or diastolic blood pressure exceeds 90 mmHg), high total cholesterol level (above 5.2 mmol/L), low high-density lipoprotein level (less than 0.9 mmol/L), smoker, history of microalbuminuria or past vascular disease
    4) Treatment of the following clinical symptoms in diabetic patients: Early nephropathy with microalbuminuria (30­300mg/24h), overt glomerular nephropathy, proteinuria (>500mg/24h)
    – Treatment of non-diabetic overt glomerular nephropathy (when creatinine clearance is 20-70 mL/min) or proteinuria (≥3g/24h)

TOP